Inner Mongolia Furui Medical Science Co., Ltd.

SZSE:300049 Stock Report

Market Cap: CN¥9.5b

Inner Mongolia Furui Medical Science Valuation

Is 300049 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300049 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300049 (CN¥35.91) is trading above our estimate of fair value (CN¥3.9)

Significantly Below Fair Value: 300049 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300049?

Key metric: As 300049 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300049. This is calculated by dividing 300049's market cap by their current earnings.
What is 300049's PE Ratio?
PE Ratio73.3x
EarningsCN¥130.40m
Market CapCN¥9.45b

Price to Earnings Ratio vs Peers

How does 300049's PE Ratio compare to its peers?

The above table shows the PE ratio for 300049 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.8x
600771 GuangYuYuan Chinese Herbal Medicine
138.5xn/aCN¥9.5b
600664 Harbin Pharmaceutical Group
15.9xn/aCN¥9.6b
300181 Zhejiang Jolly PharmaceuticalLTD
22x23.3%CN¥11.1b
002020 Zhejiang Jingxin Pharmaceutical
14.8x14.4%CN¥10.4b
300049 Inner Mongolia Furui Medical Science
73.3x47.1%CN¥9.5b

Price-To-Earnings vs Peers: 300049 is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the peer average (47.8x).

Price to Earnings Ratio vs Industry

How does 300049's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300049 73.3xIndustry Avg. 29.2xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300049 is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the CN Pharmaceuticals industry average (29.2x).

Price to Earnings Ratio vs Fair Ratio

What is 300049's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300049 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.3x
Fair PE Ratio40.5x

Price-To-Earnings vs Fair Ratio: 300049 is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the estimated Fair Price-To-Earnings Ratio (40.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.85

7D

-10.1%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥37.2b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.97

7D

-1.7%

1Y

17.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.9b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.29

7D

-0.7%

1Y

16.7%